Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12416941 | 0.89 | HTR7 (0.41) | LMNAMAPT | |
| SCHEMBL2215081 | 0.89 | HTR7 (0.41) | LMNAMAPT | |
| SCHEMBL16589448 | 0.79 | POLB (0.42) | ALDH1A1KMT2ALMNAGAAHPGD | |
| SCHEMBL7565543 | 0.78 | ALDH1A1 (0.43) | ALDH1A1KMT2ALMNAGAAHPGD | |
| SCHEMBL7565547 | 0.78 | ALDH1A1 (0.43) | ALDH1A1KMT2ALMNAGAAHPGD | |
| SCHEMBL11991815 | 0.76 | PSEN1 (0.51) | ALDH1A1KMT2ALMNAGAAMCOLN3 | |
| SCHEMBL16589446 | 0.75 | NPSR1 (0.36) | ALDH1A1KMT2ALMNAGAAMCOLN3 | |
| SCHEMBL16220192 | 0.75 | PSEN1 (0.50) | ALDH1A1 | |
| SCHEMBL4574469 | 0.74 | POLB (0.40) | ALDH1A1KMT2ALMNAGAAHPGD | |
| SCHEMBL15015455 | 0.74 | ACHE (0.38) | ALDH1A1KMT2ALMNAMCOLN3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546422-B2 | Azaindole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2013-10-01 | — | — | US | disclosed |
| US-8546422-B2 | Azaindole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2013-10-01 | — | — | US | disclosed |
| US-20110178115-A1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178115-A1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | ALDH1A1 1288/4885KMT2A 2727/4885LMNA 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.